NurExone Biologic is a groundbreaking brand that aims to revolutionize the treatment of nervous system injuries. Their innovative approach involves using exosomes as nanocarriers to deliver therapeutic molecules, creating a healing environment through neuron rewiring and regeneration. Their first drug, ExoPTEN, has already shown promising results in laboratory rats by reversing paralysis and enabling them to walk again.

NurExone Biologic is confident that they can replicate this success in humans, offering hope to those who have experienced acute spinal cord injuries. But their vision extends beyond spinal cord injuries. As pioneers in the field of medicine and biology, NurExone Biologic is continually pushing the boundaries and developing new technologies and intellectual property.

This opens up exciting possibilities for other applications and indications, driving early revenues and generating value for shareholders. Join NurExone Biologic on their mission to regenerate and rewire neurons, creating a platform technology that is non-invasive, cell-free, and off the shelf. With their revolutionary approach, they aim to reverse the devastating effects of nervous system injuries and provide a new ray of hope for patients